Medifast MED Payments for Repurchase of Other Equity
Payments for Repurchase of Other Equity at other companies
Other financials
Where this comes from
Reported directly by Medifast in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfOtherEquity.
The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medifast's payments for repurchase of other equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medifast's payments for repurchase of other equity?
- Medifast (MED) reported payments for repurchase of other equity of $814K in Q1 2026.
- How has Medifast's payments for repurchase of other equity changed year-over-year?
- Medifast's payments for repurchase of other equity increased by 120.6% year-over-year, from $369K to $814K.
- What is the long-term trend for Medifast's payments for repurchase of other equity?
- Over 3 years (2021 to 2024), Medifast's payments for repurchase of other equity has grown at a -48.4% compound annual growth rate (CAGR), from $6.09M to $836K.
- What does payments for repurchase of other equity mean?
- This represents the cash outflow associated with the company's repurchase of its own equity instruments or other related equity securities. It is a key component of capital allocation strategy, reflecting how the company returns value to shareholders or manages its capital structure. Tracking these payments helps investors assess the company's commitment to share buybacks and its overall financial flexibility.